Pharmaron’s Clinical Pharmacology Center (CPC), located in Baltimore, Maryland, is a full-service Phase 1 clinical trials facility, featuring 96 beds across four First-in-Human (FIH) and two radiolabel (14C-hADME) dosing suites.
Quick study start-up and flexible scheduling allow Pharmaron to consistently meet sponsor timelines, with 100% recruitment, over 99% retention for short-term studies, and more than 95% retention for studies lasting up to two years.
Pharmaron’s experienced team, purpose-built facility, and strategic location work together to deliver operational excellence to ensure precision, consistency, and integrity across all studies. Five full-time Principal Investigators (PIs) also provide continuous availability and expert clinical oversight from start to finish.
Key areas of expertise:
- Integrated First-in-Human (FIH) studies
- 14C human ADME studies
- Vaccine and infectious disease research
- Ethnobridging studies
End-to-end clinical trial management
Pharmaron also offers full-service support for early-phase clinical trials, including:
- Regulatory affairs
- Patient and volunteer management
- Medical writing and monitoring
- Pharmacovigilance
- Quantitative pharmacology
Download your free copy of the eBook today to learn how Pharmaron’s CPC can help you move confidently through early clinical development.
About Pharmaron
Pharmaron is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 17,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.